What Amsel Medical Corp does

Amsel Medical Corporation is a privately held, pre-commercialization medical device company founded in 2011 in Cambridge, Massachusetts by vascular surgeon Arnold Miller, MD. The company develops the SCureClamp platform built on its proprietary Interdigitation Occlusion Technology (iDOT) — a mechanical transfixing clamp delivered through an 18-gauge needle that achieves permanent vessel occlusion without chemical, thermal, or compressive mechanisms. iDOT's anchoring feature uses interdigitation to eliminate slippage, enabling secure occlusion of veins, arteries, and tubular structures ranging from 2.0 mm to 7.0 mm in diameter, comparable to a hand-sewn transfixion suture.

The cleared product family includes the SCureClamp with iDOT (also marketed as the Amsel Occluder Device), the Amsel Endo Occluder (FDA 510(k) cleared August 2024 for endoscopic use), and the SCureTO trauma solution in development for junctional and non-compressible hemorrhage. Three FDA 510(k) clearances and a CE Mark have been secured across these products; peer-reviewed preclinical evidence has been published in the Journal of Vascular Surgery, Journal of Surgical Endoscopy, and Journal of Surgical Research. Clinical evaluation has been conducted at NYU Langone and UCLA Medical Center, and a know-how agreement with Mayo Clinic was signed in February 2023.

Amsel's go-to-market strategy is enterprise field sales targeting vascular surgeons, interventional radiologists, general and cardiovascular surgeons, and military medical personnel. To date the company has generated no commercial revenue; development has been financed primarily through non-dilutive U.S. Air Force/AFWERX SBIR contracts (including a $7.45M Phase III sole-source award in 2024 and a $1.5M TACFI grant in 2021) and equity raises from angel groups such as Boston Harbor Angels and Cherrystone Angel Group. Future revenue is expected to come from hardware sales of SCureClamp devices and appliers to hospitals, surgical centers, and military medical facilities upon commercialization.

Name

Amsel Medical Corp

Legal name

Amsel Medical Corporation

Website

https://amselmedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Amsel Medical Corp is a pre-commercialization medical device company developing the SCureClamp platform with proprietary Interdigitation Occlusion Technology (iDOT) for mechanical, minimally invasive vessel occlusion, targeting vascular surgeons, interventional radiologists, general surgeons, and military medical personnel.

Ownership category

akta.pro rank

Product category

Surgical Vessel Occlusion Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

akta.pro secondary industries

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Surgical clamping devices
• Vessel occlusion technology
• Medical device manufacturing
• Interventional radiology devices
• Hemorrhage control devices

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: As a pre-commercialization stage company, Amsel Medical generates no commercial revenue to date. The SCureClamp with iDOT has received FDA 510(k) clearance and CE mark clearance for open general surgery. Revenue will be derived from sale of the SCureClamp device and its appliers to hospitals, surgical centers, and military medical facilities upon commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Amsel Medical Corporation develops and manufactures the SCureClamp with Interdigitation Occlusion Technology (iDOT), a mechanical surgical clamping device delivered through an 18 G needle for percutaneous occlusion of blood vessels, ducts, arteries, and veins during surgical and interventional procedures. The device family includes the FDA 510(k) cleared and CE Marked Amsel Occluder Device, the FDA cleared Amsel Endo Occluder for endoscopic procedures, and the SCureTO trauma solution in development for military junctional hemorrhage control. The proprietary iDOT anchoring feature secures the implant and eliminates slippage, providing transfixion-grade occlusion without chemical, thermal, tumescent, or compressive mechanisms.

Product overview

Amsel Medical Corp offers a platform technology called Interdigitation Occlusion Technology (iDOT) with multiple product applications. The core product SCureClamp with iDOT provides minimally invasive surgical clamping delivered via 18G needle for vessel occlusion. The company has received three FDA Clearances and a CE Mark Clearance covering various surgical applications including general surgery, endoscopic procedures, and vascular interventions. The SCureTO trauma solution is under development for military hemorrhage control applications. All products leverage the proprietary iDOT anchoring mechanism that secures implants in place and eliminates slippage.

Differentiator

Problem solved

Functional benefit

Brands

• SCureClamp: FDA cleared and CE marked surgical clamping device with Interdigitation Occlusion Technology (iDOT) designed to close vessels during surgical and interventional procedures.
• SCureTO

Products and services

• SCureClamp with Interdigitation Occlusion Technology (iDOT)

Quantifiable outcome

• SCureClamp with iDOT occludes vessels more securely than standard Ligaclip with comparable tissue safety in porcine model (Journal of Surgical Research, Oct 2016)
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core, minor and supporting.

• Mayo CliniccoreStrategic or Co-development PartnerAmsel Medical signed a know-how agreement with Mayo Clinic to advance the development of its occlusion technology. The collaboration brings together Amsel's patented iDOT platform with Mayo Clinic's clinical know-how in vessel occlusion (veins, arteries, and tubular structures) during surgical and interventional procedures in vascular trauma, vascular access, and other interventional procedures.
• Night Stalker FoundationminorOthersAmsel Medical supported the Night Stalker Foundation's 30th Anniversary commemoration of Gothic Serpent (Battle of Mogadishu, 'Black Hawk Down'), honoring the service and sacrifice of the 160th Special Operations Aviation Regiment (Airborne).
• M2D2 (Mass Medical Device-to-Market Accelerator)supportingImplementation/ SI/ Consulting PartnerAmsel Medical was selected into the M2D2 IMPACT Cycle 4 accelerator program, a 12-week one-on-one program supporting medtech companies advancing toward commercialization.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Penumbra: Penumbra develops interventional vascular devices including the Indigo aspiration system for thrombectomy and embolization. Comparable as a focused, high-growth vascular intervention company with overlapping customer call points.
• Inari Medical: Inari Medical has built a high-growth franchise in venous thromboembolism and peripheral vascular intervention. Comparable in being a focused vascular specialist with strong clinical-evidence-driven adoption — a relevant growth and exit comparable.
• Silk Road Medical: Silk Road Medical pioneered transcarotid artery revascularization (TCAR), building a focused vascular franchise with strong clinical evidence. Comparable in being a single-platform, indication-focused vascular device company that scaled via clinical data and KOL engagement.

Broad incumbents

• Stryker: Stryker has a substantial surgical instruments and emergency/trauma portfolio through its收购 of Wright Medical and other medtech assets. Relevant peer as a potential strategic acquirer given CEO Heinz's prior roles at Zimmer and Smith/Nephew in orthopedics and trauma.
• Ethicon (Johnson & Johnson): Ethicon manufactures the Ligaclip metal ligation clip — the standard-of-care incumbent that Amsel positions its iDOT device against. Directly comparable as the dominant incumbent in the vessel occlusion category Amsel is targeting.
• Medtronic (VNUS): Medtronic acquired VNUS Medical Technologies and dominates the chronic venous disease market with ClosureFast RF ablation — competing head-to-head with Amsel's primary commercial vertical of varicose vein and perforator treatment, where SCureClamp claims superior efficacy over RF ablation (75-80% efficacy benchmark).
• Boston Scientific: Boston Scientific is a diversified medical device leader with peripheral vascular and closure device franchises, plus senior leadership overlap (VP Quality Stephen Mager previously at Boston Scientific). A potential strategic acquirer for vessel occlusion IP.
• Abbott Vascular: Abbott's vascular division offers vessel closure devices (Perclose, StarClose) used in percutaneous interventional procedures — directly comparable to Amsel's percutaneous ultrasound-guided SCureClamp delivery in vascular access closure.
• Teleflex (Vascular Solutions): Teleflex acquired Vascular Solutions and offers a portfolio of vascular closure and interventional devices sold to vascular surgeons and interventional radiologists — directly overlapping with Amsel's primary customer base and vessel-occlusion use cases.

Direct peers

• AngioDynamics: AngioDynamics manufactures vascular and peripheral intervention devices, including embolization plugs and vessel occlusion tools. It directly competes in vessel closure for vascular surgeons and interventional radiologists — Amsel's core customer segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amsel-medical-corp

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amsel Medical Corp